KRAS-IN-5

• Description:

  KRAS-IN-5 (Compound Ex 6) is an orally active and selective inhibitor targeting KRAS mutants (including KRASG12D, KRASG12V, KRASWT) with a GNE IC50 value of 1.3 nM against KRASG12D. KRAS-IN-5 blocks tumor cell proliferation by inhibiting KRAS-mediated signaling pathways (e.g., reducing ERK phosphorylation) . KRAS-IN-5 is promising for research of KRAS mutation-related cancers, such as pancreatic cancer, colorectal cancer, lung cancer[1].

• UNSPSC:

  12352005

• Target:

  Ras

• Related Pathways:

  GPCR/G Protein; MAPK/ERK Pathway

• Field of Research:

  Cancer

• Smiles:

  FC1=C(CC)C2=C(C=C(NN=C3C)C3=C2C4=C(F)C(N=C(OC[C@@]56CCCN5C[C@H](F)C6)N=C7N(CCCOC8)[C@@H]8CO9)=C7C9=N4)C=C1

• Molecular Formula:

  C35H36F3N7O3

• Molecular Weight:

  659.70

• References & Citations:

  [1]Shuhei Kawamura, et al. Small molecule inhibitors of kras proteins. WO2025085748A1. 2025-04-24.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• Isoform:

  K-Ras

• CAS Number:

  [3082412-00-5]